MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
LivaNova PLC Net Debt 2011-2025 | LIVN
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt LivaNova PLC
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 130 M | 310 M | 11.8 M | -187 M | 401 M | 272 M | 121 M | 52.4 M | 56.7 M | -124 M | -103 M | -121 M | -96.7 M | -82.3 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 401 M | -187 M | 45.8 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Abiomed
ABMD
|
-227 M | - | - | $ 17.2 B |  USA |
 |
Acutus Medical
AFIB
|
14.2 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B | USA |
 |
Apyx Medical Corporation
APYX
|
-10.1 M | $ 3.6 | - | $ 125 M | USA |
 |
Boston Scientific Corporation
BSX
|
8.64 B | $ 96.13 | 0.04 % | $ 141 B | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | USA |
 |
Bio-Rad Laboratories
BIO
|
754 M | $ 301.75 | 0.24 % | $ 8.51 B | USA |
 |
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | USA |
 |
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | USA |
 |
Eargo
EAR
|
-97.8 M | - | - | $ 10.2 M | USA |
 |
BioSig Technologies
BSGM
|
252 K | - | 37.08 % | $ 85.7 M | USA |
 |
Cardiovascular Systems
CSII
|
-64.6 M | - | 0.15 % | $ 844 M | USA |
 |
Bruker Corporation
BRKR
|
1.91 B | $ 48.12 | 0.21 % | $ 7.17 K | USA |
 |
Cutera
CUTR
|
-140 M | - | -10.19 % | $ 1.99 M | USA |
 |
Abbott Laboratories
ABT
|
5.26 B | $ 124.81 | 0.22 % | $ 217 B | USA |
 |
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-22.8 M | $ 2.97 | 4.58 % | $ 111 M |  France |
 |
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | USA |
 |
InMode Ltd.
INMD
|
-34.8 M | $ 14.47 | 0.7 % | $ 1.15 B |  Israel |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-4.95 M | - | - | $ 111 M |  Canada |
 |
Dynatronics Corporation
DYNT
|
1.8 M | - | 14.99 % | $ 929 K | USA |
 |
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
-47.4 M | $ 9.54 | - | $ 685 M | Israel |
 |
Second Sight Medical Products
EYES
|
961 K | - | -0.97 % | $ 54.4 M | USA |
 |
Align Technology
ALGN
|
-925 M | $ 157.84 | 0.69 % | $ 11.8 B | USA |
 |
NanoVibronix
NAOV
|
-636 K | - | - | $ 1.08 M | USA |
 |
Accuray Incorporated
ARAY
|
73.7 M | $ 0.86 | 0.43 % | $ 88.4 M | USA |
 |
Myomo
MYO
|
-4.79 M | $ 1.02 | 12.09 % | $ 7.19 M | USA |
 |
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | USA |
 |
ClearPoint Neuro
CLPT
|
-16.5 M | $ 14.49 | 0.84 % | $ 392 M | USA |
 |
FONAR Corporation
FONR
|
-42.8 M | $ 14.53 | 0.07 % | $ 95.2 M | USA |
 |
IRIDEX Corporation
IRIX
|
-4.29 M | $ 1.14 | 3.64 % | $ 18.4 M | USA |
 |
IRadimed Corporation
IRMD
|
-52.1 M | $ 97.06 | 0.48 % | $ 1.23 B | USA |
 |
AxoGen
AXGN
|
21.9 M | $ 32.64 | -0.61 % | $ 1.44 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-230 M | - | - | $ 3.31 B | USA |
 |
GBS
GBS
|
-4.38 M | - | -0.57 % | $ 7.12 M | USA |
 |
CONMED Corporation
CNMD
|
889 M | $ 40.17 | 1.34 % | $ 1.24 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
31.3 M | $ 17.41 | 0.75 % | $ 402 M | USA |
 |
Globus Medical
GMED
|
-774 M | $ 88.43 | -0.38 % | $ 12 B | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
529 M | $ 12.66 | 0.56 % | $ 975 M | USA |
 |
Aziyo Biologics
AZYO
|
1.36 M | - | 1.37 % | $ 20.5 M | USA |
 |
Aethlon Medical
AEMD
|
-4.85 M | $ 2.49 | -6.39 % | $ 3.89 M | USA |
|
LENSAR
LNSR
|
-13.6 M | $ 12.01 | -0.08 % | $ 138 M | USA |